These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 20354957)

  • 1. An example of the clinical selectivity of regadenoson for the A2a adenosine receptor.
    Miyamoto MI; Clarke KA; Thomas GS; Belardinelli L
    Am Heart Hosp J; 2009; 7(2):E118-21. PubMed ID: 20354957
    [No Abstract]   [Full Text] [Related]  

  • 2. Effects of adenosine and a selective A2A adenosine receptor agonist on hemodynamic and thallium-201 and technetium-99m-sestaMIBI biodistribution and kinetics.
    Mekkaoui C; Jadbabaie F; Dione DP; Meoli DF; Purushothaman K; Belardinelli L; Sinusas AJ
    JACC Cardiovasc Imaging; 2009 Oct; 2(10):1198-208. PubMed ID: 19833310
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Indirect evidence of sympathetic stimulation by regadenoson.
    Farris GR; Hage FG; Kumar V; Iskandrian AE
    J Nucl Cardiol; 2019 Apr; 26(2):684-687. PubMed ID: 29948894
    [No Abstract]   [Full Text] [Related]  

  • 4. Regadenoson: review of its established role in myocardial perfusion imaging and emerging applications.
    Palani G; Ananthasubramaniam K
    Cardiol Rev; 2013; 21(1):42-8. PubMed ID: 22643345
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Regadenoson as a new stress agent in myocardial perfusion imaging. Initial experience in The Netherlands].
    Jager PL; Buiting M; Mouden M; Oostdijk AH; Timmer J; Knollema S
    Rev Esp Med Nucl Imagen Mol; 2014; 33(6):346-51. PubMed ID: 24862658
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Myocardial perfusion imaging laboratory efficiency with the use of regadenoson compared to adenosine and dipyridamole.
    Friedman M; Spalding J; Kothari S; Wu Y; Gatt E; Boulanger L
    J Med Econ; 2013; 16(4):449-60. PubMed ID: 23363331
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the prognostic value of normal regadenoson with normal adenosine myocardial perfusion imaging with propensity score matching.
    Iqbal FM; Hage FG; Ahmed A; Dean PJ; Raslan S; Heo J; Iskandrian AE
    JACC Cardiovasc Imaging; 2012 Oct; 5(10):1014-21. PubMed ID: 23058068
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regadenoson stress for myocardial perfusion imaging.
    Reyes E
    Future Cardiol; 2016 Jan; 12(1):59-67. PubMed ID: 26639775
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Common genetic polymorphisms of adenosine A2A receptor do not influence response to regadenoson.
    Berlacher M; Mastouri R; Philips S; Skaar TC; Kreutz RP
    Pharmacogenomics; 2017 Apr; 18(6):523-529. PubMed ID: 28358597
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regadenoson myocardial perfusion imaging predicts prognosis in patients with either left bundle branch block or a ventricular paced rhythm.
    Thomas GS; Taghavi A
    J Nucl Cardiol; 2021 Jun; 28(3):978-980. PubMed ID: 31385224
    [No Abstract]   [Full Text] [Related]  

  • 11. Capturing maximal coronary vasodilation for myocardial perfusion imaging: is timing everything?
    Dilsizian V; Narula J
    JACC Cardiovasc Imaging; 2015 Apr; 8(4):499-500. PubMed ID: 25882579
    [No Abstract]   [Full Text] [Related]  

  • 12. Comparing prognostic value of imaging agents and imaging techniques.
    Udelson JE
    JACC Cardiovasc Imaging; 2012 Oct; 5(10):1022-4. PubMed ID: 23058069
    [No Abstract]   [Full Text] [Related]  

  • 13. Regadenoson.
    Bengalorkar GM; Bhuvana K; Sarala N; Kumar TN
    J Postgrad Med; 2012; 58(2):140-6. PubMed ID: 22718059
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ST segment elevation during adenosine pharmacological stress testing in a patient with coronary artery disease.
    Raza JA; Khan NU; Mustafa JS; Movahed A
    Am Heart Hosp J; 2009; 7(2):E122-4. PubMed ID: 20354958
    [No Abstract]   [Full Text] [Related]  

  • 15. Adenosine A2A receptor as a drug discovery target.
    de Lera Ruiz M; Lim YH; Zheng J
    J Med Chem; 2014 May; 57(9):3623-50. PubMed ID: 24164628
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regadenoson, a selective A2A adenosine receptor agonist, causes dose-dependent increases in coronary blood flow velocity in humans.
    Lieu HD; Shryock JC; von Mering GO; Gordi T; Blackburn B; Olmsted AW; Belardinelli L; Kerensky RA
    J Nucl Cardiol; 2007 Jul; 14(4):514-20. PubMed ID: 17679059
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Daily Caffeine Consumption Is Associated with Decreased Incidence of Symptoms and Hemodynamic Changes During Pharmacologic Stress with Regadenoson.
    Posch MI; Kay MD; Harhash AA; Huang JJ; Krupinski EA; Abidov A; McMillan NA; Kuo PH
    J Nucl Med Technol; 2020 Mar; 48(1):73-76. PubMed ID: 31604901
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The heart rate response to regadenoson in patients with atrial fibrillation.
    Uzendu AI; Iskandrian A; Hage FG
    J Nucl Cardiol; 2018 Jun; 25(3):1012-1016. PubMed ID: 28856613
    [No Abstract]   [Full Text] [Related]  

  • 19. Regadenoson.
    Garnock-Jones KP; Curran MP
    Am J Cardiovasc Drugs; 2010; 10(1):65-71. PubMed ID: 20063904
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advances in pharmacologic stress agents: focus on regadenoson.
    Johnson SG; Peters S
    J Nucl Med Technol; 2010 Sep; 38(3):163-71. PubMed ID: 20724531
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.